2026 International Congress » Parkinson’s Disease: Clinical Trials

12-week Aerobic Interval Training Induces Hemisphere-Specific Neuroprotection in Parkinson’s Disease: A Multimodal MRI, [18F]Fluorodopa PET/CT and BDNF Study

K. Lorek, B. Kossowski, A. Marchewka, M. Chalimoniuk, J. Langfort, J. Mączewska, L. Królicki, K. Markowska, S. Budrewicz, M. Koszewicz, Z. Wroński, J. Marusiak (Wroclaw, Poland)

A 6-month Pilot Study of Disease-Modifying Potential of Long-term Transcutaneous Auricular Vagus Nerve Stimulation in Parkinson’s Disease

JX. Shi, KZ. Zhang (Nanjing, China)

A Phase 1b Study to Investigate Safety, Tolerability and Biomarker Responses of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease

K. Holmström, K. Jääskeläinen, N. Kulesskaya, A. Ludwig, J. Koskinen, A. Vuolanto, A. Domanska, M. Engström, S. Määttänen, P. Vainio, M. Scheinin, C. Videbaek, Z. Lovro, F. Scheperjans, J. Rinne, H. Huttunen (Espoo, Finland)

A Phase I Multicenter Trial of a Novel Gene Therapy BBM-P002 for Parkinsons Disease

M. Niu, J. Lin, J. Liu (Shanghai, China)

A Randomized Controlled Trial Evaluating Ankle Pump Combined with Compression Abdominal Belts on Orthostatic Hypotension in Patients with Parkinson’s Disease

Z. Ruan, YY. Zhang, WH. Guo, JY. Liu (Beijing, China)

A Retrospective Comparison of Multiple Approaches to LFP-guided and Imaging Guided Contact Selection in Subthalamic Deep Brain Stimulation for Parkinson’s Disease

SH. Herstell, CST. Schedlich-Teufer, ES. Schmehr, JS. Strelow, GB. Brandt, VVV. Visser-Vandewalle, TD. Dembek, MB. Barbe (Cologne, Germany)

Acupuncture Combined with Anti-Parkinson Medication Improves Objective Balance Parameters in Patients with Parkinson’s Disease

X. Liu, Q. Liu, SM. Lin, MY. Yan, YX. Wu, JQ. Fan, YF. Zhang, LX. Zhuang (Guangzhou, China)

Age-related characteristics of the clinical progression of Parkinson’s disease

B. Muminov, R. Matmurodov, B. Amonov, S. Jumanazarova (Tashkent, Uzbekistan)

Agreement Between Patient-Reported Experiences of Daily Living and Clinician-Rated Motor Exam Severity in Parkinson’s Disease

A. Silva, M. Kalb, J. Agin-Liebes (New York, USA)

Allogeneic iPSC-Derived Dopaminergic Progenitor Transplantation for Parkinson’s Disease: A Phase 1, Dose-Escalation Trial

D. Su, X. Wang, J. Zhang, X. Zheng, J. Luo, Z. Wang, L. Ma, J. Xi, P. Yan, X. Li, F. Meng, T. Feng (Beijing, China)

ALPHA-FIT: Slowing cognitive decline in alpha-synucleinopathies by enhancing physical activity

E. Fitzgibbon, M. Wildt, T. Oosterhof, M. Rodemann, A. Ophey, E. Prins, S. Darweesh, A. Stefani, M. Sommerauer (Bonn, Germany)

An Ongoing Phase 1/2, Multi-center, Open Label Study of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease

M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Chengdu, China)

Azathioprine-associated changes in peripheral–central immune signalling in Parkinson’s disease: post-hoc analysis of AZA-PD

J. Greenland, J. Holbrook, R. Pal, L. Kahanawita, K. Dresser, E. Cutting, C. Williams-Gray (Cambridge, United Kingdom)

Barriers to Disease-Modifying Clinical Trials in Parkinson’s Disease: A Survey of Clinicians and Researchers Involved in Clinical Trials

J A. de Marcaida, K. Kearney, S. Mccarthy, G. Woolery, K. Hespeler, M. Hespeler, S. Dewitte, A. Espay (Vernon, USA)

Baseline Characteristics of Participants Enrolled in a Randomised Pilot Study of Enhanced Tai Chi for Parkinson’s disease

M. Qamar, O. Awogbemila, R. Savla, L. Batzu, S. Rota, A. Hernandez Pena, C. Yang, M. Freris, B. Dikong, J. Whitney (London, United Kingdom)

Can people with Parkinson’s disease improve gait adaptation skills via upregulation of the posterior parietal cortex?

T. Ogawa, C. Guedes, C. Mvomo, L. Hajjaji, J. Bedime, A. Potvin-Desrochers, C. Paquette (Montreal, Canada)

Can Voice Therapy Improve Swallowing in Advanced Parkinson’s Disease? A Comparison of SPEAK OUT!® Outcomes in Patients With Deep Brain Stimulation and Medical Therapy

N. Likhitwitayawuid, S. Jitwiriyanont, K. Nantanukul, R. Bhidayasiri, O. Phokaewvarangkul (Bangkok, Thailand)

Cannabis-based Oil for Pain and Other Non-motor Symptoms in Parkinson’s Disease: a Randomized Controlled Trial

A. Alves, J. Parmera, G. Kubota, P. Martins, M. Deltreggia, A. Falcone, A. Santana, M. Falcão, M. Dias, L. Moreira, P. Filho, E. Figueiredo, E. Barbosa, R. Cury, D. Andrade (Juiz de Fora, Brazil)

Changes in Continuous Good ON and Best ON Time During the Waking Day With Tavapadon in People With Parkinson’s Disease

R. Hauser, R. Dhall, D. Kremens, L. Harmer, K. Chan, J. Ma (Tampa, USA)

Clinical and Mobility Outcome with Ring versus Directional Globus Pallidus Stimulation in Parkinson’s Disease

A. Ragothaman, J. Lee, V. Massicotte, G. Harker, P. Carlson-Kuhta, L. Neilson, C. Zarns, M. Case, R. Vigh, A. Becker, R. Raike, K. Burchiel, M. Mancini, D. Safarpour (Portland, USA)

Clinical Drug-Drug Interaction Profile Of BIA 28-6156: Results From Three Independent Phase I Studies

TF. Fonseca, AR. Ronaghinia, JR. Reis, DR. Rodrigues, AN. Neves, GC. Cordeiro, RC. Costa, FR. Rocha, DM. Magalhães, AG. Guimarães, JH. Holenz (Coronado, Portugal)

Clinical Evaluation of TT-P34: Exploring Safety and CSF Exposure in Parkinson’s Disease Patients

A. Borta, K. Comassi, S. Singh, E. Browne, A. Dalby, S. Korsten, M. Aaboe Jørgensen, G. Layton, J. Castricum, S. Mølgaard, P. Kremer (Leiden, Netherlands)

Clinical impact of local field potential sensing–guided deep brain stimulation: a real‑world registry

J. Youn, S. Bick, P. Konrad, M. Schiess, T. Theys, T. Witt, H. Mure, H. Oshima, K. Kimura, G. Oyama, H. Kishima, N. Murase, Y. Tsuboi, A. Fasano, T. Brionne, I. Buffin, G. Choi, X. Sun, Y. Ren, T. Weaver (Seoul, Republic of Korea)

Clustered Difference of Gut Microbiome in Helicobacter pylori-negative and positive Group Effect on Clinical Motor Symptoms in PD (Helicobacter pylori-Stool Microbiome or HP-SM Trial)

W. Wongpipathpong, N. Srivanitchapoom, M. Utharntharm, P. Pongchaikul, N. Tungtrongchitr (Samut Prakan, Thailand)

Cognitive and neuropsychiatric effects of home-based, remotely supervised strength exercise combined with guideline-based aerobic physical activity modification in Parkinson’s Disease: a randomized controlled trial

R. Kim, B. Byun, K. Kang, S. Choi, J. Lee, B. Jeon (Seoul, Republic of Korea)

Comparative Effectiveness of Tavapadon Versus Real-world Oral Standard of Care Treatments in Parkinson’s Disease With Motor Fluctuations: an Indirect Comparison Analysis

P. Agarwal, R. Pahwa, A. Fasano, H. Deng, C. Yan, L. Harmer, S. Huang, K. Onuk, A. Espay (Kirkland, USA)

Comparative efficacy and safety of Safinamide versus Opicapone in Japanese patients with Parkinson’s Disease and wearing-off: A matching-adjusted indirect comparison

N. Nishikawa, R. Ando, T. Ishida, T. Hatano, N. Hattori, M. Nomoto (Tokyo, Japan)

Complete Resolution of Troublesome Dyskinesia in People With Advanced Parkinson’s Disease Treated With Foslevodopa/Foscarbidopa: Post Hoc Analysis From a 52-Week Phase 3 Trial

R. Hauser, A. Antonini, D. Di Luca, E. Freire-Alvarez, M. Oliveira Fernandes, M. Shah, L. Bergmann, X. Li, M. O’Meara, D. Standaert (Tampa, USA)

Continued Evaluation of Clinical Outcomes in Participants With Parkinson’s Disease Through 4 Years After Bemdaneprocel Administration

C. Henchcliffe, H. Sarva, A. Fasano, A. Lozano, S. Kalia, KKH. Yu, C. Brennan, M. Louie-Gao, N. Floro, G. Belfort, V. Tabar (Toronto, Canada)

Decentralized Clinical Trial of a Phase 3 Light Therapy Device for Parkinson’s Disease: Feasibility, Safety, and Efficacy

S. Hussain, C. Alessi-Fox, M. Kostrzebski, K. Murphy, M. Porto, K. Schmier, K. Clark, A. Mcgarry, J. Adams, K. Hendrix, S. Hendrix, D. Adams, E. Dorsey, AND. The Light-Pd Investigators (San Francisco, USA)

Demystifying the Delivery of Multi-arm Multi-stage Platform Trials for Parkinson’s Disease –Framework and Recommendations from EJS ACT-PD

C. Girges, J. Inches, L. Brennan, G. Mills, M. Zeissler, E. de Pablo-Fernandez, C. Pugh, C. Gonzalez-Robles, R. Gurney, S. Collins, C. Murphy, C. Carroll, T. Foltynie (Plymouth, United Kingdom)

Development and initial feasibility of a Randomised Pilot Trial of Enhanced Tai Chi for Parkinson’s Disease

M. Qamar, O. Awogbemila, R. Savla, L. Batzu, S. Rota, A. Hernandez Pena, C. Yang, M. Freris, B. Dikong, J. Whitney (London, United Kingdom)

Discontinuation of Parkinson’s Disease Clinical Studies: A Cross-Sectional Analysis

Y. Alnomani, A. Mady (Benha, Egypt)

Disease-Modifying Outcomes Following High Intensity Boxing and Sensory Exercise in Parkinson’s Disease: Results From a Double-blinded Randomized Controlled Trial

K. Sangarapillai-Patel, Q. Almeida (Waterloo, Canada)

Dual-Site Transcranial Magnetic Stimulation Ameliorates Freezing of Gait in Parkinson’s Disease by Remodeling Cortical Excitatory-Inhibitory Balance and White Matter Microstructure: A Randomized Controlled Trial

C. Gan, K. Zhang (Nanjing, China)

EAGLE: Protocol for a Phase 3 Study to Evaluate the Efficacy and Safety of Two Mobile Applications Combined with Immediate-Release CD/LD for the Management of Idiopathic Parkinson’s Disease

S. Oren, A. Amedi, S. Molcho, D. Ziv, O. Shoval, S. Erlich (Ramat Gan, Israel)

Effect of a Live-streaming Tele-exercise in Parkinson’s Disease: a Multicenter, Controlled Trial in South Korea

S. Yoon, J. Ha, J. Youn, J. Cho (Seoul, Republic of Korea)

Effectiveness of Acupuncture for Parkinson’s Disease with Mild Cognitive Impairment A Randomized Clinical Trial

II. Leong, SN. Wu, JQ. Fan, LX. Zhuang (Guangzhou, China)

Effectiveness of Proprioceptive Neuromuscular Facilitation (PNF)-based exercise in people with Pisa syndrome from Parkinson’s disease: a case report

ISK. Wong-Yu, YYE. Chan, HYC. Shiu, PSR. Liu, KY. Cheung (Hong Kong SAR, China)

Effects of a Motor–Cognitive eHealth‑Supported Home Exercise Program on Walking Difficulties and Performance in Parkinson’s Disease

J. Sedhed, H. Johansson, E. åkesson, E. Franzén, B. Leavy (Huddinge, Sweden)

Effects of Auricular Vagus Nerve Stimulation Combined with Neurorehabilitation on Motor Symptoms, Balance, and Gait in People with Parkinson’s Disease: Preliminary Results of a Prospective Study

M. Salamci, A. Guclu-Gunduz, M. Akbostanci (Ankara, Turkey)

Effects of Bright Light Therapy On Sleep And Functional Brain Networks In Parkinson’s Disease-A Pilot Trial

H. Li, Y. Shen, C. Liu (Suzhou, China)

Effects of Targeted Memory Reactivation during Sleep on Motor Memory Consolidation in Parkinson’s Disease

L. Micca, G. Albouy, B R. King, A. Nieuwboer, W. Vandenberghe, P. Borzée, B. Buyse, D. Testelmans, J. Nicolas, M. Gilat (Salt Lake City, USA)

Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Gastrointestinal Function in Parkinson’s Disease: A Preliminary Randomized Controlled Trial

Z. Zhu, H. Zhang, H. Wang, Y. Geng, Y. Yuan, K. Zhang (Nanjing, China)

Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Motor Function in Parkinson’s disease; A Prospective, Multicenter, Crossover Study

SJ. Lee, HA. Kim, JE. Kim, MS. Shin, DY. Kown, HW. Shin (Seoul, Republic of Korea)

Evaluating a Decision Aid for Deep Brain Stimulation in Parkinson’s Disease: Results of a Pre–Post Pilot Study

M. Fullard, D. Kern, E. Shelton, A. Dafoe, M. Morris, D. Matlock (Aurora, USA)

Evaluating Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease in the Chinese Population (ADAPT-PD China Study)

H. Shang, B. Sun, J. Wu, Y. Zhang, N. Zhang, A. Xie, L. Chen, J. Zhang, Y. Tan, T. Goble, H. Berrier, S. Stanslaski (Shanghai, China)

Evaluation of Swallowing and Cough Function in older Patients with Parkinson’s Disease

M. Nakamori, M. Toko, H. Yamada, R. Matsuyama, Y. Hayashi, M. Yoshikawa, T. Nagasaki, H. Maruyama (Hiroshima, Japan)

Exploratory Efficacy Analysis of Tavapadon Versus MAO-B Inhibitors in People With Early Parkinson’s Disease

E. Freire Alvarez, K. Chan, J. Eubanks, J. Ma, E. Peckham (Alicante, Spain)

Exposure-Response Analysis of Glovadalen in the ATLANTIS Phase II Study: Trial Simulation Explains Dose-Response for OFF Time in Parkinson’s

D. Menshykau, M. Biagioni, C. Beuter, C. Legendre, A. Benoit, L. Vroye, B. Klünder, M. Faisal, S. Leach, R. Nicholl, H. Naik (Monheim am Rhein, Germany)

First-in-Human Single-Ascending-Dose Trial of ALN-SNCA, an Intrathecally Administered siRNA for Reducing α-synuclein, in Patients with Early-Stage Parkinson’s Disease

M. Ahmed, M. Effendi, S. Schneider, M. Rosario, M. Magliocca, A. Gorbenko, B. Bugna, L. Farrelly, P. Kremer, R. Postuma, J. Whitton, A. Avbersek, O. Harari (Tarrytown, USA)

Five‑Year Outcomes Following Unilateral MR‑Guided Focused Ultrasound Pallidotomy in Parkinson’s Disease

A. Fasano, A. Sokolov, K. Gant, A. Grinspan (Toronto, Canada)

Foslevodopa-Foscarbidopa Continuous Subcutaneous Infusion Leads to Long-Term Reduction in Dyskinesia in Parkinson’s Disease: Results from 5-Year Follow-Up

N. Jeyakumar, P. Becker, M. Georgiades, D. Tsui, X. Chen, S. Bray, J. Qiu, S. Waller, L. Williams, S. Dal, T. Ong, A. Martin, H. Morales-Briceno, V. Fung (Sydney, Australia)

Frequency-Specific Effects of SMA-rTMS on Gait Initiation in Parkinson’s Disease

Y. Chen, Y. Wang, Y. Wang, J. Jiang, C. Xu, F. Chung, M. Pang, M. Mak, M. Huang (Kowloon, Hong Kong)

Global Momentum in Parkinson’s Disease Therapeutics: Ten-Year Trends in Mechanisms, Modalities, and Clinical Endpoints

L. Gutiu, A. Fuller, A. Todorova (Durham, USA)

Heterogeneous Responsiveness to Combined Motor–Cognitive Exercise in Parkinson’s Disease: A Latent Class Analysis

J. Hwang, C. Youm, H. Park, M. Kim, B. Kim, S. Cheon (busan, Republic of Korea)

High-Frequency rTMS for Cognitive Impairment in Parkinson’s Disease: A Randomized Sham-Controlled Trial in Veterans

Y. Kim, S. Walker, K. Colletta, A. Umbarger, S. Kletzel (Maywood, USA)

High-Intensity Multimodal Training Through Group-Based Weighted Dance for Parkinson’s Disease: A Feasibility Study

Y. Chen, S. Lai, C. Xu, K. Liu, L. Lo, T. Cheng, C. Li, C. Lui, Y. Wang, J. Jiang, Y. Wang, M. Huang (Kowloon, Hong Kong)

Identification of Phenotypes in a Prospective Parkinson’s Disease Cohort Using Digital Wearable Monitoring

A. Saenz, I. Gabilondo, S. Seijo, A. Ochoa, U. Zalabarria, I. Cuenca, B. Tijero, T. Fernández, M. Ruiz, M. Acera, J. Gomez, R. Del Pino (Barakaldo, Spain)

Identifying Peripheral Stimulation Sites to Treat Parkinson’s Disease Gait Impairments

N. Hennessy, M. Bravo, J. Fallon, M. Shoushtarian (East Melbourne, Australia)

Impact of Hula on Balance Outcomes in Parkinson’s Disease

M. Yee, P. Young, R. Shuman, C. Stickley, M. Bruno (Honolulu, USA)

Improved “Good On” Time and Reduced Motor Fluctuations After Switching to IPX203: Interim Real-World Results from the First 111 Patients in ELEVATE PD

R. Hauser, S. Isaacson, S. Betté, A. Richmond, M. Jay, G. Banisadr, S. Fisher, H. Visser (Tampa, USA)

IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 7-year Interim Results

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, M. van Zandijcke (Bruges, Belgium)

Intranasal spray for nose-to-brain drug delivery: Emergency treatment of OFF episodes in Parkinson’s disease

Y. Tang, X. Yue, E. Liang, C. Wu (Guangzhou, China)

IPX203 Achieves High Responder Rates Independent of Fluctuation Severity: Insights From RISE‑PD

R. Hauser, J. Kopra, I. Marjanovic, G. Goisis, M. Knecht (Tampa, USA)

Join Parkinson’s Research (JPR@Research+Me): A UK-wide registry to support clinical trial recruitment in Parkinson’s disease

C. Stewart, M-L. Zeissler, R. Davidson, K. Hockey, G. Mills, J. Lamb, T. Liddle, T. Foltynie, Y. Yiannakou, C. Carroll (Newcastle upon Tyne, United Kingdom)

Levodopa Initiation in Phase 3 Trials of Tavapadon, a Selective D1/D5 Agonist for Early Parkinson’s Disease

W. Ondo, G. Stebbins, J. Eubanks, M. Rollins Hatcher, T. Nicholson, J. Ma (Houston, USA)

Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease

R. Pozzi, T. Ignoni, M. Bosetti, A. Barassi, M. Desciscio, A. Lehn, R. Schwartz, D. Thyagarajan, J. Taylor, J. Hannestad (Lugano, Switzerland)

Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, May Improve Motor Complications in People with Parkinson’s Disease: Results from an 18-week open-label, Phase 1b Trial

AM. Højer, A. Cucca, C. Linander, L. Creuwels, M. Pedersen, D. Meulien (Copenhagen, Denmark)

Mass balance and metabolism of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase, in humans

A. Loureiro, A. Ronaghinia, F. Sousa, D. Almeida, R. Costa, J. Holenz, M. Bonifácio (Coronado, Portugal)

Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’

B. Ribba, T. Nikolcheva, P. Pierrillas, C. Diack, A. Monnet, B. Ricci, M. May, G. Pagano, G. Kerchner, P. Brundin (Basel, Switzerland)

Move-Brain-PD: a Randomized Multicenter Protocol of Remotely Monitored Home-based Aerobic Exercise for Parkinson’s Disease Patients with Mild Cognitive Impairment

AT. Cimmino, G. Di Lazzaro, D. Genovese, VL. Marian, IF. Ivan, RM. Scheytt, AR. Bentivoglio, TF. Outeiro, C. Falup-Pecurariu, P. Calabresi (Goettingen, Germany)

Neuromodulation of Add-on Repetitive Transcranial Magnetic Stimulation improving Freezing of Gait in Parkinson’s Disease: Integrated Cross-sectional and Interventional Evidence

C. Gan, K. Zhang (Nanjing, China)

NLRP3 Inhibition in Early-Stage Parkinson’s disease: Results of a Phase Ib Study

G. Pagano, B. Zinnhardt, N. Shariati, B. Ricci, M. Tagliati, A. Noyce, B. Bloem, H. Sarva, R. Kumar, K. Marek, K. Brockmann, T. Simuni, D. Standaert, N. Pavese, M. Politis, N. Milani Muelhardt, G. Kerchner, L. Kulic, A. Bonni (Basel, Switzerland)

Noninvasive Electrosonic Brain Stimulation for Parkinson’s Disease: Results from a Phase II Trial

F. Fregni, P. Teixeira, P. Gonzalez-Mego, A. Lepesteur Gianlorenco, C. Ramos-Estebanez, T. Wagner, L. Dipietro (Cambridge, USA)

Opicapone as adjunct to levodopa in Chinese patients with Parkinson’s disease and wearing-off: a randomized, double-blind, placebo-controlled phase 3 trial

S. Chen, Y. Tan (Shanghai, China)

Opicapone for Management of Sleep Disturbances in Parkinson’s Disease: Post-hoc Analysis of the OASIS trial in Patients With and Without Probable RBD

G. Banisadr, J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, S. Fisher, J. Holenz, C. Trenkwalder (Bridgewater, USA)

Outcomes from Unilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy for Advanced Parkinson’s Disease

H. Sarva, K. Gant, C. Modak, C. Ferrer, A. Sokolov, A. Grinspan (New York, USA)

Patient-Defined Disease Progression in Parkinson Disease: Towards Patient-Relevant Outcome Measures

C. Gonzalez-Robles, A. Schrag, R. Weil, M. Burnell, G. Mills, ML. Zeissler, J. Carpenter, S. Gandhi, C. Carroll, T. Foltynie (London, United Kingdom)

Pharmacoscintigraphic Evaluation and Safety of a Novel, Dual-pulse, Delayed-release carbidopa/levodopa Tablet for Bedtime Dosing

A. østerskov, A. Elvang, T. Sager, K. Christensen, F. Macdougall, L. Corry (Horsholm, Denmark)

Phase 1 Study of BT-267, a potent, selective, brain-penetrant, and oral small molecule inhibitor of LRRK2

T. Dam, D. Hilt, E. Remeeva, A. Mathias, M. Mcgill, K. Dokukina, A. Pushechnikov, R. Karapetyan, V. Kazey, I. Dukes, N. Savchuk (Dover, USA)

Phase 1 Study of BT-409, a potent, selective, brain-penetrant, and oral small molecule inhibitor of NLRP3 in Healthy Volunteers and Adults with Parkinson’s disease

T. Dam, A. Mathias, E. Remeeva, D. Hilt, M. Mcgill, A. Pushechnikov, R. Karapetyan, N. Savchuk, I. Dukes, V. Kazey, K. Dokukina (Dover, USA)

Phase 2 Trial for the Treatment of Early-stage Parkinson’s Disease with TJ0113, a Small Molecule Mitophagy Activator

W. Luo, ZD. Cen, XF. Cen, XH. Chen, S. Wu, Y. Tan, LQ. Mao, XL. Mao, B. Zhang, W. Lv, SZ. Liu, YP. Wang, D. Liu, HG. Xia (Zhejiang, China)

Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study

T. Nikolcheva, G. Pagano, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, N. Pross, A. Monnet, G. Kerchner, P. Brundin, A. Bonni (Basel, Switzerland)

Pulse-Width Dependent Motor Performance in Deep Brain Stimulation of Subthalamic Nucleus in Parkinson’s Disease: Evidence for a Kinematic Optimum Near 50 µs in Hand Movement

P. Köberle, N. Banaschewski, Y. Cordes, G. Adacay, J. Volkmann, M. Reich, F. Lange (Würzburg, Germany)

Qihuang Needle Therapy for Motor Symptoms in Parkinson’s Disease: A Randomized Controlled Trial

WQ. Peng, RH. Zhao, ZT. Huang, NB. Wang, ZH. Chen (Guangzhou, China)

Randomized Controlled Trial Comparing Adaptive versus Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease; Closed Loop Optimization of Deep Brain Stimulation Effect in Parkinson’s Disease (CLOSE-PD study)

J. Genet, M. Heeren, B. Keulen, D. Hubers, B. Swinnen, F. Contarino, M. Janssen, Y. Temel, B. van Wijk, A. Hillebrand, M. Bot, R. Schuurman, R. de Bie, M. Beudel (Leuven, Belgium)

Real-World Impact of “Off” Time Reduction with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of the ROSSINI Study

W. Jost, T. Henriksen, S. Hassin-Baer, R. Hauser, L. Bergmann, M. O'Meara, S. Pan, J. Parra, M. Shah, J. Aldred (Wolfach, Germany)

Reframing Treatment Paradigms: The Rise of Cell and Gene Therapies in Parkinson’s Disease

L. Gutiu, A. Fuller, A. Todorova (Durham, USA)

Rehabilitation Following Initiation of Device Assisted Treatment in Parkinson’s Disease – a Randomized Controlled Trial

A. Björkdahl, A. Khalif, M. Gustafsson, A. Lindström, F. Bergquist (Gothenburg, Sweden)

Relationship between automatic analysis of gait disorder and eye movement capture by AI and cognitive function in Parkinson’s disease

J. Cheng, JZ. Hu, XY. Cheng, CJ. Mao (Suzhou, China)

Relationship Between Perceived and Actual Gluteal Muscle Activation in Parkinson’s Disease

K. Kakegawa, T. Matsuda, J. Ogawa, Y. Soutome (Bunkyo-ku, Japan)

Responsiveness of a Smartphone-Based Sensor-Derived Composite Endpoint in a Phase 2b Study in Parkinson’s Disease (PD)

R. Llorens Arenas, E. Bartholome, S. Belachew, C. Bernasconi, G. Cosne, A. Ena, J. Guo, B. Hersh, D. Jennings, A. Juraver, C. Kanzler, A. Karatsidis, F. La Pietra, M. Pang, ó. Reyes, A. Rodríguez-Romero, M. Wald, P. Wang, M. Yang, C. Mazzà (Cambridge, USA)

Responsiveness of Sensor-Derived Measures From a Smartphone-Based Active Typing Test in the Phase 2b LUMA Study of Parkinson’s Disease

R. Llorens Arenas, E. Bartholome, S. Belachew, C. Bernasconi, G. Cosne, J. Guo, B. Hersh, D. Jennings, A. Juraver, C. Kanzler, A. Karatsidis, M. Pang, ó. Reyes, A. Rodríguez-Romero, M. Wald, P. Wang, M. Yang, C. Mazzà (Cambridge, USA)

Restoring the Axis: Efficacy of Fecal Microbiota Transplantation (FMT) on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2023–2025)

Z. Hussein, A. Al-Zaidi, F. Al-Zaidi (Salahddin, Iraq)

Robot-Assisted Transplantation of Hypoimmune iPSC Derived Dopaminergic Progenitor Cells for Idiopathic Parkinson’s Disease

J. Shi, J. Yu, C. Han, A. Chen, L. Jiao, R. Qian (Hefei, China)

Robot-Assisted Transplantation of Hypoimmune iPSC-Derived Dopaminergic Progenitor Cells for PRKN-EOPD

J. Guo, J. Shi, Y. Zhang, C. Han, L. Yao, L. Jiao, R. Qian, J. Yu, A. Chen (Hefei, China)

Sensory–Motor Discrepancy of Arm Swing During Gait in Parkinson’s Disease

T. Matsuda, K. Kakegawa, J. Ogawa, Y. Soutome, R. Onuma, T. Kawasaki, Y. Fujino (Bunkyo, Japan)

Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults with Hyposmia

V. Azoidou, T. Oosterhof, E. Mitchell, B. Bloem, C. Philpott, S. Darweesh, A. Noyce (London, United Kingdom)

Slow-SPEED-US: Initiation of a Remote Exercise Trial in LRRK2 and GBA1 Carriers

R. Schneider, T. Oosterhof, E. Prins, M. Kmiecik, S. Aslibekyan, N. Hetrick, M. Porto, K. Schmier, C. Dorney, A. Noyce, B. Bloem, S. Darweesh (Rochester, USA)

Switching to IPX203 from IPX066 Significantly Improves “Good On” Time and Reduces Motor Fluctuations Under Real-World Conditions

R. Hauser, M. Bixby, D. Bega, R. Dewey, Iii, G. Banisadr, S. Fisher (Tampa, USA)

Switching to IPX203 Significantly Increases the Duration of “Good On” Intervals: Interim Real-World Results from the First 111 Patients in ELEVATE-PD

S. Isaacson, L. Cloud, D. Kreitzman, S. Brillman, G. Banisadr, S. Fisher, R. Hauser (Boca Raton, USA)

Systemic antioxidant response to bilateral anodal transcranial direct current stimulation in Parkinson’s disease: findings from a pilot randomized controlled study

H. Hadoush, A. Al-Sharman, S. Banihani (Sharjah, United Arab Emirates)

Temporally Patterned Deep Brain Stimulation Improves Gait Metrics and Freezing of Gait in Parkinson’s Disease

S. Song, H. Azgomi, A. Sayaseng, R. Ramesh, H. Bokil, S. Niketeghad, D. Wang (San Francisco, USA)

The Allosteric Activator of Lysosomal Glucocerebrosidase VQ-101 Demonstrates Robust Evidence of Target and Pathway Engagement in People with Parkinson’s Disease: Results from a 6-Month Open-Label Extension Study

M. Facheris, J. Valk, I. Koopmans, K. Hunt, M. Hagey, O. Siddiqui, P. Kremer, J. Sullivan, D. Ysselstein (Chicago, USA)

The Clinical and Biological effects of a Whole Foods and Plant-Based Dietary Intervention in Parkinson’s Disease

B. Boon, S. Meles, B. Bloem, T. van Laar, E. Postma (Groningen, Netherlands)

The Emerging Landscape of Genotype-Stratified Clinical Trials in Parkinson’s Disease and Atypical Parkinsonian Disorders

YY. Beh, SY. Lim, AM. Abdul Sahak, L. Lange, K. Brolin, A. Noyce, M. Nalls, A. Singleton, H. Morris, AH. Tan (Kuala Lumpur, Malaysia)

The GLP-1 Agonist Paradox in Parkinson’s Disease: A Comparative Analysis of Lixisenatide and Exenatide Phase III Trial Outcomes and Neuroprotective Mechanisms

F. Al-Zaidi (Almaty, Kazakhstan)

Trans-Spinal Theta Burst Stimulation for Axial Symptoms in Parkinson´s Disease with Deep Brain Stimulation A Randomized Clinical Trial

A. Rocha, J. Simões, S. Santos, R. Carra, J. Oliveira, G. Nunes, C. França, I. Paraguay, S. Casagrande, M. Carvalho, P. Martins, E. Barbosa, R. Cury (Salvador, Brazil)